Featured Editorial

  1. Digital Endpoints Are Ready. Clinical Development Isn't 5/7/2026

    Regulatory guidance and validation science for digital endpoints are solid. The real barrier is cross-functional execution – and the cost of waiting is compounding.

  2. Why Clinical Trial Data Cleaning Must Go Continuous (And How To Do It) 5/4/2026

    Cleaning data is no longer an afterthought; it’s a continuous, risk-based must-have that protects integrity, ensures compliance, and drives reliable results.

  3. What Clinical Analytics Solutions Are Shaping Clinical Research 5/4/2026

    Clinical analytics solutions, powered AI/ML and enabled by cloud computing, are indispensable assets in clinical research. Discover the latest technologies being leveraged for faster, more cost-effective, and personalized clinical trials.

  4. Sites Are Building Their Own Tech – SCRS On What That Means 4/30/2026

    SCRS’s Jimmy Bechtel on why Bring-Your-Own-Tech is both a protest and a performance differentiator, and what the industry needs to do about it.

  5. Human-In-The-Loop In AI Validation And Control: From Principle To Practice 4/28/2026

    Explores how human-in-the-loop oversight can move from principle to practice. with a risk-based framework for determining when HITL is required, how the human role should be defined, and what organizational factors influence its effectiveness.

  6. When The System Breaks, Who Pays? SCRS On Site Tech Gaps 4/27/2026

    SCRS CSSO Jimmy Bechtel on why clinical site tech integration is an architecture problem – and who bears the risk when remote systems fail.

  7. HTA, Digital Twins, And Building Clinical Tech That Lasts 4/24/2026

    ISPOR CEO Rob Abbott on HTA-integrated trial design, digital twin evidence gaps, SaMD’s continuous update problem, and the one change he’d mandate for clinical tech.

  8. Real-World Evidence And Wearables Are Reshaping Trial Tech 4/22/2026

    ISPOR’s Rob Abbott on why RWE moved to number two in the 2026-2027 HEOR Trends Report, and what wearables, data fragmentation, and HARPER+ mean for clinical platforms.

  9. Navigating Elsa's AI Transition: Practical Guidance To Safeguard Confidential Information (Part 3) 4/22/2026

    With FDA's Claude-to-Gemini transition underway within Elsa, Kimberly Chew, Esq., and Michael Yang, Esq., offer advice for proactive risk management to safeguard trade secrets and regulatory outcomes in part three of this series on Elsa's AI transition.

  10. HEOR, AI, And The Future Of Clinical Trial Technology 4/20/2026

    ISPOR CEO Rob Abbott on why HEOR must be in the room when clinical trial tech is built, and what ISPOR’s latest Top 10 HEOR Trends Report means for ClinOps.